Depo-Medrol on Psoas After LLIF

Part of paid clinical trials in Farmington, Connecticut.

Sponsor
Hardeep Singh
Study ID
NCT05929755
Phase
PHASE4
Status
Recruiting
Apply to this trial

Conditions

  • Muscle Weakness
  • Pain, Muscle
  • Pain, Postoperative
  • Paresthesia

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Depo-Medrol — DRUG
    steroid
  • Gel-Flow NT — DRUG
    hemostatic agent

Study Details

The goal of this study is to determine the effects of a corticosteroid administered to the psoas muscle following a transpsoas lateral lumbar interbody fusion (LLIF) on postoperative hip flexor weakness and thigh pain and numbness.

Key Dates

Start date
May 12, 2023
Status verified
Jul 2025
Primary completion
Aug 31, 2025
Completion
May 31, 2027

Study Design

Enrollment
80 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER

Arms

  • Placebo Comparator: Control group (standard care)
    1 cc gel foam powder mixed with thrombin
  • Experimental: Test group (standard care + study intervention)
    1 cc of gel foam powder mixed with thrombin and 80mg Depo-Medrol

Primary Outcome Measure

Quantify the difference in thigh pain measured on the visual analog pain scale (VAS) between those receiving a depo-medrol injection and those who did not over 3 postoperative time periods: 2-3, 6, and 12 weeks following surgery. [ Time Frame: 2-3 weeks following surgery ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
UConn HealthFarmingtonConnecticut06030
Study Coordinator
[email protected]
Hardeep Singh, M.D. (PRINCIPAL_INVESTIGATOR)
Isaac Moss, M.D., C.M., M.A.Sc., FRCSC (SUB_INVESTIGATOR)
Scott Mallozzi, M.D. (SUB_INVESTIGATOR)

Find similar trials in Farmington, CT

By research site
UConn Health· Farmington, CT

Related Studies